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Outcomes of Reduced-Intensity Conditioning
with Fludarabine and Melphalan for Allogeneic
Hematopoietic Stem Cell Transplantation
Jonas A. de Souza,1,2 Rima M. Saliba,1 Poliana Patah,3 Gabriela Rondon,1 Rachel Ribeiro,1
Leandro de Padua Silva,1 Muzaffar H. Qazilbash,1 Chitra Hosing,1 Uday Popat,1
Yvonne Efebera,1 Richard E. Champlin,1 Marcos de Lima1Nonrelapsemortality (NRM) after reduced-intensity allogeneic transplants is likely to be influenced by abnor-
malities in renal function. We studied 141 patients diagnosed with acute myelogenous leukemia (AML)
(n5 131) or high-risk myelodysplastic syndrome (MDS) (n5 10) who underwent allogeneic transplantation
with fludarabine (Flu)/melphalan (Mel)-based regimens and hypothesized thatmoderate tomild renal function
impairment increasesNRM in this setting. Flu dose consisted of 25-30mg/m2 for 4 days andMel dosewas 100-
180 mg/m2. Donors were HLA-compatible siblings (n5 69) andmatched unrelated donors (n5 72). Disease
status at transplantation was complete remission (n5 56, 40%) or active disease (n5 85, 60%). The influence
of the estimated glomerular filtration rate (GFR)measured before transplantation on outcomeswas analyzed.
GFR was estimated by both the Cockcroft-Gault (CG) and the modified diet in renal disease (MDRD) equa-
tions, using the creatinine value obtained prior to starting chemotherapy. Evaluated outcomes were overall
survival (OS), NRM, and treatment-related mortality (TRM) at day 100 and 1-year posttransplantation. Me-
dian age was 55 years (range: 21-74 years); 59% of the patients were male. Estimated GFR by CGwas$90 for
45 (32%), 60-89 for 78 (55%), and\60 for 18 (13%) patients.When estimated byMDRD,GFRwas$90 for 65
(46%), 60-89 from 66 (47%), and\60 for 10 (7%) patients. The majority of patients by both estimations had
a GFR between 60 and 89 (n5 78 by CG and n5 66 byMDRD)with no difference in the evaluated outcomes
between this group and the subgroup of patients with a GFR\60 (P..05). There were no differences in OS
and NRM at day 100 and 1-year posttransplantation in the 3 groups by any GFR estimation method. In con-
clusion, a mild to moderate decrease in GFR was not associated with an increase in NRM.
Biol Blood Marrow Transplant 15: 1094-1099 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Transplantation, Toxicity, Reduced intensity, Renal function, CreatinineINTRODUCTION
Renal injury is a common complication of hemato-
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Consequently, impairment of renal function is often
used as an exclusion criterion when selecting patients
who undergo HCT. Acute myelogenous leukemia
(AML) and myelodysplastic syndrome (MDS) are dis-
eases of the elderly, a population usually with some de-
gree of renal impairment, frequently worsened by
previous chemotherapy and exposure to a variety of
nephrotoxic drugs.
Nonmyeloablative (NMA) conditioning regimens
were developed as less toxic modalities of treatment
for the elderly population and those with serious co-
morbidities who are not eligible for standard myeloa-
blative (MA) HCT [3]. As proposed by Champlin
et al. [4,5], the definition of a truly nonablative regimen
is one that can be given routinely without stem cell sup-
port, with neutrophil recovery within 28 days, and one
in which mixed chimerism can be routinely detected
early after transplantation. Regimens that cannot be
Biol Blood Marrow Transplant 15:1094-1099, 2009 1095Renal Function and Outcomes of Reduced-Intensity Allogeneic HCTsafely administered without stem cell support have
been termed reduced-intensity conditioning (RIC)
[6]. AtM.D. AndersonCancerCenter, we use the com-
bination of a purine analog (fludarabine [Flu]) with an
alkylating agent (melphalan [Mel]) [3,6-11].
We hypothesized that patients with AML/MDS
and renal impairment before the administration of
the Flu/Mel regimen would have worse outcomes, in-
cluding higher nonrelapse mortality (NRM), than
those with a normal renal function. The hypothesis
was investigated in a homogeneous patient population
including only AML/MDS patients that received RIC
and allogeneic HCT.METHODS
Eligibility
Patients were included in this retrospective analy-
sis if they had either AML or high-risk MDS and had
undergone an allogeneic HCT from an HLA-compat-
ible donor with an RIC regimen with Flu/Mel. Pa-
tients were treated under consecutive protocols, and
were eligible to receive Flu/Mel if older than 50 years,
or in the presence of clinical comorbidities that pre-
cluded the use of myeloablative conditioning. Patients
were also selected on the basis of having a creatinine
level\1.6 mg/dL. Patients that received a previous al-
logeneic transplant were excluded. From August 1996
until May 2006, a total of 141 patients met these eligi-
bility criteria and were included in the present analysis.Reduced-Intensity regimen
All subjects signed written informed consents, and
their treatment protocols and this study were approved
by our institutional review board (IRB). Patients
received Flu 25 to 30 mg/m2 for 4 to 5 days in combi-
nation with melphalanMel 100, 140, or 180mg/m2 to-
tal dose. Antithymocyte globulin (ATG) was added for
recipients of unrelated (UD) or mismatched related
donor HCT. Graft-versus-host disease (GVHD) pro-
phylaxis consisted of tacrolimus (FK506, Prograf, Fu-
jisawa, Deerfield, IL) and methotrexate (MTX) 5 mg/
m2 i.v. on days 1, 3, 6, and 11 after transplantation for
all but 2 patients. Tacrolimus levels were monitored 3
times a week and kept at therapeutic ranges of 5 to 10
ng/dL during the first 100 days and then tapered at the
discretion of the primary physician depending on do-
nor type, disease status at time of transplantation, pres-
ence or absence of GVHD, and presence of residual
donor cells as documented by chimerism or cytoge-
netic analysis. Tacrolimus target levels and MTX
doses were similar regardless of baseline renal
function.
Antibacterial, antifungal, and antiviral prophylaxis
consisted of trimethoprim-sulfamethoxazole forPneumocystis jiroveciprophylaxis, acyclovir or valacyclovir
for herpes simplex virus (HSV) prophylaxis, and surveil-
lance cytomegalorivus (CMV) antigenemia testing for
all patients with preemptive use of ganciclovir in the
event of a positive antigenemia test. All patients received
filgrastim (granulocyte colony-stimulating factor
[G-CSF]) (Neupogen, Amgen, Thousand Oaks, CA)
5 mg/kg s.c. daily from day17 until achievement of an
absolute neutrophil count (ANC) above 1.5  109/L
for 3 days. Packed red blood cells were administered to
maintain hemoglobin levels greater or equal to 8 g/dL.
Platelet transfusions were administered to keep the
platelet count at a level of$10 109/L. All blood prod-
ucts were filtered and irradiated. Donor stem cells or
bonemarrow (BM)were procured using standardmobi-
lization protocols and pheresis techniques. The stem
cells or BM from all related donors were collected at
the M.D. Anderson Cancer Center, and they were pro-
cessed according to current institutional guidelines and
protocols. All healthy donors signed written informed
consent for the procedure. BM procured from UD was
obtained through theNationalMarrowDonorProgram
(NMDP) according to applicable guidelines at the time
of procurement.As requiredby theNMDP,donors gave
consent at the donor center after an extensive screening
and information process.
Renal Function Assessment
Baseline glomerular filtration rate (GFR) was
estimated the day prior to the conditioning regimen
and in other time points before and after HCT using
both the abbreviated modified diet in renal disease
(MDRD) equation: GFR (mL/min/1.73 m2) 5 186
Pcr
21.154  age20.203  (1.212 if black)  (0.742 if fe-
male) and the Cockcroft-Gault (CG) equation, GFR
(mL/min/1.73 m2) 5 (140 2 age)  (weight)/(PCr 
72) (0.85 if female), where Pcr is the plasma creatinine
level [12,13]. Pretransplantation baseline renal function
was classified into 5 stages, as suggested by theNational
Kidney Foundation (NKF) [12], and patients were
divided into 3 risk groups according to their GFR:
\60 (NKF 3, 4, and 5), 60-89 (NKF 2), $90 (NKF 1)
mL/min/1.73 m2.
Statistical Considerations
The primary endpoints were overall survival (OS),
NRM, and treatment-related mortality (TRM) on day
1100 and 1 year after transplantation. Outcomes were
estimated starting on the day of HCT. NRM was
defined as death occurring in the absence of progression
or relapse of malignancy. TRMwas defined asNRMex-
cluding deaths attributed to GVHD [14]. Actuarial OS
was estimated by the method of Kaplan-Meier. The cu-
mulative incidence method accounting for competing
risks was used to estimate the rates of TRM, NRM, ab-
solute creatinine level above1.5mg/dL, and requirement
Table 1. Patient Characteristics
Age (median) 55 years (21-75)
Sex Male 83 (59%)
Female 58 (41%)
Diagnosis AML 131 (93%)
High-risk MDS 10 (7%)
Disease status
at HCT
Active disease 85 (60%)
Remission 56 (40%)
Donor Related 69 (49%)
Matched unrelated 72 (51%)
Stem cell source Bone marrow 74 (52%)
Peripheral blood 67 (48%)
Baseline GFR (mL/min/1.73 m2) < 60 10 (7%)
MDRD 60-89 66 (47%)
$90 65 (46%)
Cockroft-Gault <60 18 (13%)
60-89 78 (55%)
$ 90 45 (32%)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; GFR, glomerular filtration rate; MDRD, Modified Diet in Renal
Disease.
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renal function were compared on univariate analysis us-
ing the Cox’s proportional hazards model. Multivariate
analysiswasnot possible because of sample size consider-
ations. All P-values presented are 2-sided. Statistical
analyses were carried out using Stata 8.0.RESULTS
The demographic and transplant characteristics of
the study cohort (N 5 141) are described in Table 1.
All patients received allografts for AML/MDS after
an RIC regimen with Flu/Mel. The median age at
transplantation was 55 years (range: 21-75 years) and
69 patients (49%) received hematopoietic cells from
HLA-matched related donors. GFR (as measured by
the MDRD equation) was \60 in 10 patients (7%),
between 60 and 89 in 66 patients (47%), and $90 in
65 patients (46%). The corresponding proportions
per the CG equation were 13%, 55%, and 32%. De-
mographic and disease-related characteristics were
comparable in patients with a CG \60, 60-89 and
$90, except for age, which was older in the groupTable 2. PatientCharacteristicsAccording to theGlomerular Filtra
CG <60 (n 5 18) CG 6
Median age (range) 61 (25-74) 5
Age >50 years 72%
Median prior chemotherapy regimens (range) 1 (0-6)
Donor type
Related 56%
Unrelated 44%
Disease status at HCT
CR 33%
Other 67%
Median GFR (range) 51 (27-58) 7
Median absolute creatinine value (range) 1.0 (0.8-1.9) 1.
CR indicates complete remission; GFR, golmeruler filtration rate; HCT, hemawith CG\60 (median: 61 years, P 5 .03) as seen in
Table 2.
Most of the patients with renal function impair-
ment, had it for at least 1 month prior to transplanta-
tion. For the subgroup with baseline GFR \60
(calculated using the MDRD method), the median
GFR was 56 (range: 39-77), and half of the patients
had a GFR\60. As measured by the CG method, pa-
tients with baseline GFR\60 had a median GFR of 56
(range: 23-106); 75% of the patients in this group had
a GFR\60 a month prior to transplantation. These
patients had several risk factors for renal impairment.
The hematopoietic stem cell transplantation-specific
comorbidities index (HCT-CI) [15] score was equal
to or greater than 3 in 16 cases. Coexisting comorbid
conditions included cardiac disease (heart failure, n
5 3; arrhythmia, n 5 3; coronary artery disease, n 5
5), and hypertension (n 5 10). In addition, 1 patient
had diabetes, and 8 patients had a history of prior treat-
ment for a malignancy.
We investigated if the administration of commonly
used nephrotoxic drugs (including amphotericin B,
foscarnet, vancomycin, and gentamicin) had an impact
on GFR on day 100 or day 180 after transplantation.
For this purpose, we collected data for the subset of pa-
tients who had GFR$60 (as measured by the MDRD
method) at the time of transplantation (N 5 131) and
who had survived up to at least 100 (n 5 98/131) and
180 (n 5 73/131) days. Survivors were then divided
into 2 groups, according to GFR on transplant day
100 and 180 (Table 3). Chi-square comparisons
showed that the proportion of patients who had re-
ceived nephrotoxic drugs was similar in patients with
GFR $60 and those with GFR \60 on both time
points, although the group with worse renal function
had a statistically insignificant higher proportion of
patients that received foscarnet and amphotericin.
The proportion of patients who received 1, 2, or 3
drugs was comparable in patients with GFR $60 or
\60 both on 100 and 180 days after HCT.
Tables 4 and 5 show outcomes according to GFR
estimated by the CG and MDRD equations, respec-
tively. Pretransplantation GFR estimated by both thetionRate (GFR) Estimated by theCockroft-Gault (CG)Method
0-89 (n 5 78) CG $90 (n 5 45) CG <60 versus $60 (P value)
7 (30-72) 47 (21-74) .03
82% 33% .3
1 (0-8) 2 (0-5) .7
53% 40%
47% 60% .4
47% 29%
53% 71% .4
4 (60-89) 107 (90-153)
0 (0.6-1.4) 0.75(0.5-1.1)
topoietic cell transplantation.
Table 3. Use of Nephrotoxic Drugs during the First 100 Days,
and Renal Function 100 and 180 Days after Transplant
GFR <60
Day 100 (%)
n 5 46
GFR $60
Day 100 (%)
n 5 52 P value
Amphotericin B
Yes 23 50% 23 44%
No 23 50% 29 56% .6
Foscarnet
Yes 20 43% 17 33%
No 26 56% 35 67% .3
Vancomycin
Yes 19 41% 21 40%
No 27 59% 31 60% .9
Gentamicin
Yes 2 4% 2 4%
No 44 96% 50 96% .6
Number of drugs
None 8 17% 13 25%
1 18 39% 20 39%
2 12 26% 14 27%
3 8 17% 5 10% .2
GFR <60
Day 180 (%)
n 5 38
GFR $60
Day 180 (%)
n 5 35
P value
Amphotericin B
Yes 18 47% 14 37%
No 20 53% 21 55% .6
Foscarnet
Yes 16 42% 11 29%
No 22 58% 24 63% .3
Vancomycin
Yes 14 37% 13 34%
No 24 63% 22 58% .9
Gentamicin
Yes 3 8% 0 0%
No 35 92% 35 92% .9
Number of drugs
None 8 21% 11 29%
1 15 39% 14 37%
2 8 21% 6 16%
3 7 18% 4 11% .4
All patients had a glomerular filtration rate (GFR) $60 prior to trans-
plant (n 5 131).
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OS, NRM, or TRM. There was a trend for a higher
day 1100 all-cause mortality, NRM, and TRM in
patients who had a baseline MDRD level $60, yet
this did not reach statistical significance. Patients
with a mild pre-HCT renal impairment (MDRD orTable 4. Outcomes and Baseline Glomerular Filtration Rate (GFR
CG 100-Day mortality n (%) HR (95% CI) P valu
All-cause mortality
<60 4 (22%) ref.
60-89 20 (26%) 1.12 (0.4-3.3) .8
$90 11 (24%) 1.04 (0.3-3.3) .9
Non-relapse mortality
<60 3 (17%) ref.
60-89 16 (21%) 1.15 (0.3-3.9) .8
$90 9 (20%) 1.1 (0.3-4.0) .9
Treatment-related mortality
<60 2 (11%) ref.
60-89 10 (13%) 1.1 (0.2-5.1) .9
$90 3 (7%) 0.6 (0.1-3.4) .5
HR indicates hazard ratio; CI, confidence interval.
*Cockroft-Gault method (mL/min/1.73 m2).CG between 60 and 89) had similar outcome to those
with normal renal function (MDRD or CG $90).
The cumulative incidence of an absolute creatinine
level above 1.5 mg/dL during the first year after the
transplantation was 37%, 41%, and 41% in patients
with a pre-HCTCG level\60, 60-80, or$90, respec-
tively (Figure 1). These rates were not significantly
different (P 5 .9). Similarly, pre-HCT CG did not
have a significant impact on the incidence of dialysis
(P 5 .08), with a cumulative incidence of 0% in pa-
tients with the worst baseline renal function (CG
\60), 15% in patients with mild renal impairment
(CG 60-89), and 4% in those with normal renal func-
tion (CG$90). Overall, 9% (n5 13) of patients in our
cohort needed dialysis (Figure 2). Ten of the dialyzed
patients had a comorbidity index score $3. Comorbid
conditions included cardiac disease (n 5 5; congestive
heart failure, arrhythmia, and coronary arterial dis-
ease), previous treatment for another neoplasia (n 5
3), and diabetes mellitus (n 5 1). Precipitating causes
included drug nephrotoxicity (n 5 7), sepsis (n 5 1),
and thrombotic thrombocytopenic purpura (n 5 3).
Interestingly, median GFR for the group with the
worse baseline renal function remained stable after
HCT (as calculated by the MDRD method): the
median was 44 (range: 31-90; n 5 9) and 48 (range:
48-63; n 5 4), respectively, at day 1 100 and at 1
year posttransplantation.DISCUSSION
Renal failure is a common complication of anymo-
dality of HCT despite recent improvements in patient
supportive care. Patients that develop kidney disease
afterNMAHCTmay have an increased risk of mortal-
ity even if they do not require dialysis or if renal func-
tion improves [16]. The reported incidence of acute
renal failure in this setting ranges from 33% to 44%
within the first 100 days [17,18], whereas that of
chronic kidney disease can be as high as 60% within 1
year [19]. Parikh and collaborators [17] found that the), as Measured by the Cockroft-Gault (CG) Method*
e 1-Year mortality n (%) HR (95% CI) P value
9 (50%) ref.
35 (45%) 0.8 (0.4-1.7) .7
24 (53%) 1.0 (0.7-1.97) .96
5 (28%) ref.
26 (33%) 1.0 (0.4-2.7) .9
14 (31%) 1.0 (0.4-2.8) .9
2 (11%) ref.
12 (15%) 1.2 (0.3-5.5) .8
6 (13%) 1.1 (0.2-5.4) .9
Table 5. Outcomes and Baseline Glomerular Filtration Rate (GFR), as Measured by the Modified Diet in Renal Disease (MDRD)
Formula*
MDRD 100-Day Mortality n (%) HR (95% CI) P-value 1-Year mortality n (%) HR (95% CI) P-value
All-cause mortality
<60 1 (10%) ref. 5 (50%) ref.
60-89 16 (24%) 2.6 (0.3-19.4) .4 29 (44%) 0.9 (0.3-2.2) .7
$90 18 (28%) 2.9 (0.4-22.2) .3 34 (52%) 1.0 (0.4-2.6) .96
Nonrelapse mortality
<60 1 (10%) ref. 3 (30%) ref.
60-89 13 (20%) 2.15 (0.3-16.4) .5 21 (32%) 1.1 (0.3-3.7) .9
$90 14 (22%) 2.3 (0.3-17.8) .4 21 (32%) 1.1 (0.3-3.7) .9
Treatment-related mortality
<60 0 ref. 1 (10%) ref.
60-89 9 (14%) cannot estimate 10 (15%) 1.5 (0.2-11.8) .7
$90 6 (9%) cannot estimate 9 (14%) 1.0 (0.2-11.1) .7
HR indicated hazard ratio; CI, confidence inteval.
HR could not be estimated for some categories because of lack of events.
*Glomerular filtration rate estimated by the Modified Diet in Renal Disease method (mL/min/1.73 m2).
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1 year was associated with the severity of kidney injury.
In another recent publication including 13 patients
(6 of which had AML/MDS) with mildly reduced
renal function before NMA allogeneic HCT, more
than half of the patients had improvement of renal
function after transplantation [20]. Nevertheless, renal
impairment is frequently used as an exclusion criterion
when selecting patients for HCT, especially when
GVHDprophylaxis with a calcineurin inhibitor is con-
templated. It is unclear if there is a threshold below
which patients with renal failure should not receive al-
logeneic HCT. Furthermore, with the increasing use
of calcineurin inhibitor-free GVHD prophylaxis, it is
likely that renal function-based limitations established
in the past will be systematically challenged in the near
future.
We hypothesized that patients with a decreased
baselineGFRwould have worse outcomes after alloge-
neic transplant, but were unable to confirm this hy-
pothesis. A mild to moderate decrease in renal
function was not associated with an increase in NRM.
OS, NRM, and TRM at day 1100 and at 1 year
were not influenced by baseline renal function, asFigure 1. Cumulative incidence of a creatinine level above 1.5 mg/dL in
the first year after transplantation. The GFR estimated by the CGmethod
did not have an impact on the incidence of renal failure after transplant.measured here. Our cohort had a median age of 55
years, but did not include a significant proportion of
patients with severe renal failure, a reflection of the
selection process that preceded transplantation. We,
however, studied a homogenous population with
AML/MDS treated with Flu/Mel, a chemotherapy
regimen that is not markedly nephrotoxic. Our cohort
was heavily pretreated and the majority of the patients
were not in remission, having failed salvage chemother-
apy. Previous studies analyzing renal function in the
context of NMA conditioning investigated patients
with a broad range of hematologic malignancies and
most of them included regimens with total body irradi-
ation (TBI) [21]. Therefore, our conclusions may not
apply to other conditioning regimens.
We found a higher rate of patients requiring
dialysis after transplantation than previously reported
[16-18]. Nine percent of patients in our cohort needed
dialysis at some point after HCT, but it is interesting
to note that they did not belong to the group with
the worst baseline renal function. In addition, the
median GFR remained stable in the survivors belong-
ing to the subgroup of patients with a baseline GFR
\60, at 100 days and 1 year after transplantation.Figure 2. Cumulative incidence of renal failure requiring dialysis in the
first year after transplantation. TheGFR as estimated by theCGequation
did not have an impact on the incidence of renal failure requiring dialysis.
Biol Blood Marrow Transplant 15:1094-1099, 2009 1099Renal Function and Outcomes of Reduced-Intensity Allogeneic HCTThere are some limitations when interpreting the
results of our study. Although the population was ho-
mogeneous in terms of diagnosis and conditioning reg-
imen, the sample size is relatively small, decreasing our
ability to control for other variables known to influence
renal function, such as blood pressure and medication
use. However, the proportion of patients that used am-
photericin, gentamicin, foscarnet, and/or vancomycin
during the first 100 days after transplantation was sim-
ilar among patients with GFR below and above 60, as
measured 100 or 180 days after HCT.
We did not intend to compare renal function in the
context of MA versus RIC regimens. However, Parikh
and collaborators [22] reported that patients undergo-
ing MA HCT have a greater incidence of severe acute
renal failure and dialysis (12% versus 3%), when com-
pared to recipients of NMA transplants.
In conclusion, a mild to moderate decrease in the
GFR is not associated with worse survival, NRM, or
TRM in patients with AML/MDS receiving RIC
HCTwith Flu/Mel. Prospective controlled studies an-
alyzing the effect of the baseline renal function in pa-
tients undergoing HCT are needed.
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